Wednesday, May 31, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home CBRNE

Omnibus BAA for Biodefense, Radiation Exposure Countermeasures

by Global Biodefense Staff
February 1, 2017

The National Institute of Allergy and Infectious Diseases (NIAID) will be soliciting proposals under a new Omnibus Broad Agency Announcement (BAA) expected to be formally released on February 21, 2017.

The BAA supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases.

The research areas anticipated to be in the NIAID Omnibus BAA include:

  • Adjuvant Development Program: Advancing novel adjuvants towards licensure for human use through immunological characterization studies and lead compound optimization
  • Radiation/Nuclear Medical Countermeasures: New approaches to mitigate and/or treat tissue injuries arising from exposure to ionizing radiation
  • Radiation/Nuclear Predictive Biomarkers and Biodosimetric Devices: Biodosimetry biomarkers and/or automated high-throughput diagnostic systems to rapidly assess levels and types of radiation exposure using minimally invasive biosamples
  • Broad-spectrum Therapeutic Products for Biodefense, Anti-Microbial Resistant Infections and Emerging Infectious Diseases: Development of broad-spectrum therapeutic products for use in post-event settings following the intentional release of a NIAID Category A, B, or C Priority Pathogen, Zika virus, or in response to naturally-occurring outbreaks of infectious diseases caused by these pathogens.
  • Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases: Development of vaccines for use in post-event settings following the intentional release of a NIAID Category A, B, or C Priority Pathogen, Zika virus, or in response to naturally-occurring outbreaks of infectious diseases caused by these pathogens.

Further details are available via Solicitation Number: HHS-NIH-NIAID-BAA2017-1.

Tags: BAABiodosimetryNIAIDRadiationSelect Agents

Related Posts

Vials of finished vaccines
Funding News

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics
Industry News

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023
Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC